SPS-XRPD Workshop

Session

Lab. vs S-XRPD

7 May 2018, 15:10

9. Applications of XRPD for Phase Identification throughout Pharmaceutical Product Development

Dr Anisha Patel (Bristol-Myers Squibb)

07/05/2018, 15:10

Monday, May 7th Afternoon (Day 1 Workshop)

Small molecule APIs can exist in a variety of distinct solid-state forms with drastically different physicochemical properties. During development of these APIs, many factors are considered during form selection, such as stability, manufacturability, bioavailability, and intellectual property. If solid-state changes are observed during development, these selection factors can be negatively...

21. Synchrotron studies on amorphous pharmaceuticals

Prof. Lynne Taylor (Purdue University)

07/05/2018, 15:35

Monday, May 7th Afternoon (Day 1 Workshop)

28. In house and synchrotron based atomic PDF studies on non-crystalline drugs: is there room for both ?

Dr Valeri Petkov (Dept. Physics, Central Michigan university)

07/05/2018, 16:00

Monday, May 7th Afternoon (Day 1 Workshop)

Pharmaceutical industry is entering a new era in drugs development involving a transformation from crystalline to non-crystalline drug formulations. The driving force of the transformation is the largely improved bioavailability of the latter in comparison to the former. Non-crystalline drugs, however, are both an opportunity and challenge for pharmaceutical research and development (R&D). In...